Biopharmaceutical company DiscGenics recently finished enrollment for its clinical trial of IDCT, an allogeneic, injectable disc cell therapy for degenerative disc disease.
Three insights:
1. IDCT's safety and efficacy will be evaluated in 60 participants with single-level, mild to moderate lumbar degenerative disc disease.
2. The Phase 1/2 clinical trial aims to show IDCT's ability to reduce inflammation and restore disc height.
3. The prospective, randomized trial will take place at 14 centers in 12 states.